International Journal of Antimicrobial Agents
Volume 25, Issue 5 , Pages 398-403 , May 2005

Optimization of empirical antibiotic selection for suspected Gram-negative bacteraemia in the emergency department

  • Shmuel Benenson

      Affiliations

    • Infectious Diseases Unit, Shaare Zedek Medical Center, P.O. Box 3235, Jerusalem 91031, Affiliated with the Ben-Gurion Faculty of Medicine, Be’er-Sheva, Israel
    • ,
  • Amos M. Yinnon

      Affiliations

    • Infectious Diseases Unit, Shaare Zedek Medical Center, P.O. Box 3235, Jerusalem 91031, Affiliated with the Ben-Gurion Faculty of Medicine, Be’er-Sheva, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972 2 655 5076; fax: +972 2 666 6840.
    • ,
  • Yechiel Schlesinger

      Affiliations

    • Infectious Diseases Unit, Shaare Zedek Medical Center, P.O. Box 3235, Jerusalem 91031, Affiliated with the Ben-Gurion Faculty of Medicine, Be’er-Sheva, Israel
    • ,
  • Bernard Rudensky

      Affiliations

    • Clinical Microbiology Laboratory, Shaare Zedek Medical Center, Jerusalem, Affiliated with the Ben-Gurion Faculty of Medicine, Be’er-Sheva, Israel
    • ,
  • David Raveh

      Affiliations

    • Infectious Diseases Unit, Shaare Zedek Medical Center, P.O. Box 3235, Jerusalem 91031, Affiliated with the Ben-Gurion Faculty of Medicine, Be’er-Sheva, Israel

Received 2 November 2004 ,Accepted 29 January 2005.

References 

  1. Norman NJ. Sepsis. In:  Betts RF,  Chapman SW,  Penn RL editor. A practical approach to infectious diseases. 5th ed.. Philadelphia: Little Brown; 2003;p. 48–54
  2. Young LS. Sepsis syndrome. In:  Mandell GL,  Bennett JE,  Dolin R editor. Principles and practice of infectious diseases. 5th ed.. Philadelphia: Churchill Livingstone; 2000;p. 806–819
  3. Chamberland S, L’Ecuyer J, Lessard C, et al. Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. The Canadian Study Group. Clin Infect Dis. 1992;15:615–628
  4. Ristuccia AM, Cunha BA. The aminoglycosides. Med Clin North Am. 1982;66:303–312
  5. Neu HC. Clinical use of aminoglycosides. In:  Whelton A,  Neu HC editor. The aminoglycosides. New York: Marcel Dekker; 1982;p. 611–628
  6. Modai J. Treatment of serious infections with intravenous ciprofloxacin. French Multicenter Study Sroup. Am J Med. 1989;30:243S–247S
  7. Quintero-Perez NP, Andrade-Villaneuva JF, Leon-Garnica G, et al. Efficacy and safety of intravenous ciprofloxacin in the treatment of serious infections. A comparison with ceftazidime. Am J Med. 1989;30:198S–201S
  8. Finch RG. Ciprofloxacin: efficacy and indications. J Chemother. 2000;12(1):5–7
  9. Harbath S, Garbino J, Pugin J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003;115:529–535
  10. Elhanan G, Sarhat M, Raz R. Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with community-acquired bacteremia due to urinary tract infection. J Infect. 1997;35:283–288
  11. Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 1998;244:379–386
  12. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115:462–474
  13. MacArthur RD, Miller M, Albertson T, et al. Adequacy of empiric antbiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis. 2004;38:284–288
  14. Yinnon AM, Schlesinger Y, Gabbay D, Rudensky B. Analysis of five years of bacteremias: importance of stratification of microbial susceptibilities by source of patients. J Infect. 1997;35:17–23
  15. Raveh D, Rudensky D, Schlesinger Y, Attias D, Yinnon AM. Trends in bacteremias: analysis of 7544 patient-specific bacteremic episodes spanning 11 years (1990–2000). J Hosp Infect. 2003;55:196–203
  16. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing. 10th informational supplement. NCCLS document M100-S10. Wayne, PA: NCCLS; 2000.
  17. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991;100:1619–1636
  18. Antonelli M, Mercurio G, Di Nunno S, Recchioni G, DeAngelis G. De-escalation antimicrobial chemotherapy in critically ill patients: pros and cons. J Chemother. 2001;13:218–223
  19. Raveh D, Levy Y, Schlesinger Y, et al. Longitudinal surveillance of antibiotic use in the hospital; Indications for, and management of antimicrobial agents. Quart J Med. 2001;94:141–152
  20. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999;159:2562–2572
  21. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med. 2002;162:682–688
  22. Diekema DJ, Pfaller MA, Jones RN, et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program 1997. Clin Infect Dis. 1999;29:595–607
  23. Osteo J, Campos J, Baquero F. and Spanish members of the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother. 2002;50:945–952
  24. Siegman-Igra Y, Fourer B, Orni-Wasserlauf R, et al. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis. 2002;34:1431–1439
  25. Pena C, Albareda JM, Pallares R, et al. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother. 1995;39:520–524
  26. Lynch JM, Hodges GR, Clark GM, Dworzack DL. Gram-negative bacteremias. Analysis of factors for clinical assessment of gentamicin resistance. Arch Intern Med. 1981;141:582–586
  27. Leibovici L, Konisberger H, Pitlik SD, Samra Z, Drucker M. Predictive index for optimizing empiric treatment of Gram-negative bacteremia. J Infect Dis. 1991;163:193–196
  28. Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant klebsiella and Escherichia coli in nursing homes. JAMA. 1999;281:517–523
  29. Gaynes RP, Weinstein RA, Chamberlin W, Kabins SA. Antibiotic-resistant flora in nursing home patients admitted to the hospital. Arch Intern Med. 1985;145:1804–1807
  30. Muder RR, Brennen C, Drenning SD, Stout JE, Wagener MM. Multiply antibiotic-resistant gram-negative bacilli in a long-term-care facility: a case-control study of patient risk factors and prior antibiotic use. Infect Control Hosp Epidemiol. 1997;18:809–813
  31. Friedmann R, Hamburger R, Shulman C, Yinnon AM, Raveh D. Antimicrobial susceptibilities of urinary pathogens in a multidisciplinary long-term care facility. Diagn Microbiol Infect Dis. 2003;46:217–222
  32. Bonadio M, Meini M, Spitaleri P, Gigli C. Current microbiological and clinical aspects of urinary tract infections. Eur Urol. 2001;40:439–444
  33. Leibovici L, Greenshtain S, Cohen O, Wysenbeek AJ. Toward improved empiric management of moderate to severe urinary tract infections. Arch Intern Med. 1992;152:2481–2486

☆ This work was presented in part at the 13th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10–13, 2003, Glasgow, UK.

PII: S0924-8579(05)00053-1

doi: 10.1016/j.ijantimicag.2005.01.019

International Journal of Antimicrobial Agents
Volume 25, Issue 5 , Pages 398-403 , May 2005

Article Tools

* Image Usage & Resolution